Candidate therapeutic targets against acute myeloid leukemia identified via screening combinatorial peptide and chemical libraries

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Unknown venue

• Publication date

  2015-05-29

• Fields of study

  Medicine, Chemistry

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Immunotherapy in acute myeloid leukemia

  2015cited by this paper
• Targeting the interleukin-11 receptor α in metastatic prostate cancer: A first-in-man study

  2015cited by this paper
• Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.

  2014cited by this paper
• Concise Review: Leukemia Stem Cells in Personalized Medicine

  2014cited by this paper
• Functional Integration of Acute Myeloid Leukemia into the Vascular Niche

  2014cited by this paper
• A distinct glucose metabolism signature of acute myeloid leukemia with prognostic value.

  2014cited by this paper
• Cell-based strategies to manage leukemia relapse: efficacy and feasibility of immunotherapy approaches

  2014cited by this paper
• Advances in understanding the leukaemia microenvironment

  2014cited by this paper
• The Epigenetic Landscape of Acute Myeloid Leukemia

  2014cited by this paper
• Novel Target for Peptide-Based Imaging and Treatment of Brain Tumors

  2014cited by this paper
• Enhancing reproducibility in cancer drug screening: how do we move forward?

  2014cited by this paper
• Harnessing the immune system for cancer therapy

  2014cited by this paper
• Age-related clonal hematopoiesis associated with adverse outcomes.

  2014cited by this paper
• The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatment

  2014cited by this paper
• Prognostic significance of vascular endothelial growth factor expression in adult patients with acute myeloid leukemia: a meta-analysis

  2013cited by this paper
• A Systematic Mammalian Genetic Interaction Map Reveals Pathways Underlying Ricin Susceptibility

  2013cited by this paper
• Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients.

  2013cited by this paper
• Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.

  2013cited by this paper
• Immunotherapeutic strategies for relapse control in acute myeloid leukemia.

  2013cited by this paper
• Lnk adaptor suppresses radiation resistance and radiation-induced B-cell malignancies by inhibiting IL-11 signaling

  2013cited by this paper
• Selective killing of candidate AML stem cells by antibody targeting of IL1RAP.

  2013cited by this paper
• Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia.

  2013cited by this paper
• Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening.

  2013cited by this paper
• The why and how of phenotypic small-molecule screens.

  2013cited by this paper
• MicroRNAs and other non-coding RNAs as targets for anticancer drug development

  2013cited by this paper
• Phage display as a technology delivering on the promise of peptide drug discovery.

  2013cited by this paper
• Activity of the Hypoxia-Activated Prodrug, TH-302, in Preclinical Human Acute Myeloid Leukemia Models

  2013cited by this paper
• Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.

  2013cited by this paper
• The origin and evolution of mutations in acute myeloid leukemia.

  2012cited by this paper
• Roles of the hypoxia response system in hematopoietic and leukemic stem cells

  2012cited by this paper
• The hallmarks of cancer

  2012cited by this paper
• Role of neuropilin-1 and its expression in Egyptian acute myeloid and acute lymphoid leukemia patients.

  2012cited by this paper
• Clonal architecture of secondary acute myeloid leukemia.

  2012cited by this paper
• Janus kinase deregulation in leukemia and lymphoma.

  2012cited by this paper
• LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomas.

  2012cited by this paper
• An updated patent therapeutic agents targeting MMPs.

  2012cited by this paper
• Targeting the interleukin-6/Jak/stat pathway in human malignancies.

  2012cited by this paper
• Hematopoiesis: a human perspective.

  2012cited by this paper
• Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy.

  2012cited by this paper
• Passenger Deletions Generate Therapeutic Vulnerabilities in Cancer

  2012cited by this paper
• Prognostic implications of genetic aberrations in acute myelogenous leukemia with normal cytogenetics

  2012cited by this paper
• Cancer stem cells: impact, heterogeneity, and uncertainty.

  2012cited by this paper
• Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML.

  2012cited by this paper
• Epigenetic regulation of miRNA genes in acute leukemia

  2012cited by this paper
• Targeting hedgehog in hematologic malignancy.

  2012cited by this paper
• Objective assessment of cancer genes for drug discovery

  2012cited by this paper
• Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma

  2012cited by this paper
• The developing cancer stem-cell model: clinical challenges and opportunities.

  2012cited by this paper
• The PI3K/PKB signaling module as key regulator of hematopoiesis: implications for therapeutic strategies in leukemia.

  2012cited by this paper
• High-throughput screening of surface displayed gene products.

  2012cited by this paper
• Molecular and functional characterization of early human hematopoiesis

  2012cited by this paper
• Cancer Cell Metabolism

  2012cited by this paper
• Notch signaling in mammalian hematopoietic stem cells

  2011cited by this paper
• Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state

  2011cited by this paper
• Pronounced Hypoxia in Models of Murine and Human Leukemia: High Efficacy of Hypoxia-Activated Prodrug PR-104

  2011cited by this paper
• Impact of genetic features on treatment decisions in AML.

  2011cited by this paper
• Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells.

  2011cited by this paper
• Stem cell gene expression programs influence clinical outcome in human leukemia

  2011cited by this paper
• Targeting regulatory T cells for anticancer therapy.

  2011cited by this paper
• Clonal evolution in relapsed acute myeloid leukemia revealed by whole genome sequencing

  2011cited by this paper
• Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients

  2011cited by this paper
• Angiopoietin1 contributes to the maintenance of cell quiescence in EVI1(high) leukemia cells.

  2011cited by this paper
• AML1/ETO induces self-renewal in hematopoietic progenitor cells via the Groucho-related amino-terminal AES protein.

  2011cited by this paper
• CREBBP mutations in relapsed acute lymphoblastic leukaemia

  2011cited by this paper
• Primary refractory acute myeloid leukaemia – in search of better definitions and therapies

  2011cited by this paper
• Hypoxia and expression of hypoxia-related proteins in acute myeloid leukemia.

  2011cited by this paper
• Inhibition of Stat3 expression induces apoptosis and suppresses proliferation in human leukemia HL-60 cells

  2011cited by this paper
• The bone marrow microenvironment and leukemia: biology and therapeutic targeting

  2011cited by this paper
• B‐cell receptor epitope recognition correlates with the clinical course of chronic lymphocytic leukemia

  2011cited by this paper
• Understanding drug‐likeness

  2011cited by this paper
• Niche contributions to oncogenesis: emerging concepts and implications for the hematopoietic system

  2011cited by this paper
• Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia.

  2011cited by this paper
• Current findings for recurring mutations in acute myeloid leukemia

  2011cited by this paper
• Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression

  2011cited by this paper
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• Therapeutic advances in acute myeloid leukemia.

  2011cited by this paper
• Regulatory T Cells

  2011cited by this paper
• Mouse models of cancer.

  2011cited by this paper
• Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.

  2011cited by this paper
• How were new medicines discovered?

  2011cited by this paper
• Gene mutations, epigenetic dysregulation, and personalized therapy in myeloid neoplasia: are we there yet?

  2011cited by this paper
• Unfavorable-risk cytogenetics in acute myeloid leukemia

  2011cited by this paper
• AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias.

  2011cited by this paper
• The role of Smad signaling in hematopoiesis and translational hematology

  2011cited by this paper
• The bone marrow stroma in hematological neoplasms—a guilty bystander

  2011cited by this paper
• Regulation of cancer cell metabolism

  2011cited by this paper
• Cytogenetic abnormalities in adult non-promyelocytic acute myeloid leukemia: a concise review.

  2011cited by this paper
• Diversity-oriented synthesis as a tool for the discovery of novel biologically active small molecules.

  2010cited by this paper
• Effects of STAT3 silencing on fate of chronic myelogenous leukemia K562 cells

  2010cited by this paper
• Identification of Therapeutic Targets for Quiescent, Chemotherapy-Resistant Human Leukemia Stem Cells

  2010cited by this paper
• Oxygen in stem cell biology: a critical component of the stem cell niche.

  2010cited by this paper
• Genomic analysis of acute myeloid leukemia: potential for new prognostic indicators

  2010cited by this paper
• Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs

  2010cited by this paper
• Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2

  2010cited by this paper
• Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia.

  2010cited by this paper
• Acute promyelocytic leukaemia: novel insights into the mechanisms of cure

  2010cited by this paper
• Leukaemogenesis: more than mutant genes

  2010cited by this paper
• Mesenchymal and haematopoietic stem cells form a unique bone marrow niche

  2010cited by this paper
• MicroRNA-155 Regulates Cell Survival, Growth, and Chemosensitivity by Targeting FOXO3a in Breast Cancer*

  2010cited by this paper
• Use of phage display technology for the determination of the targets for small-molecule therapeutics

  2010cited by this paper

• Role of cytokine in malignant T-cell metabolism and subsequent alternation in T-cell tumor microenvironment

  2023cites this paper